C12Y 204/99003
Alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase
Official title: Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase (2.4.99.3)
C12Y204/99003 (Alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase) appears on 3 US grants and 17 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 17
- Assignees
- 10
- Inventors
- 45
- Latest grant
- 26 Sep 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 0 | 2 |
| 2021 | 0 | 4 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 5 |
By publication year.
Recent patents
- Method for in vitro glycoengineering of antibodies26 Sep 2023US 11,767,342 B2Hoffmann-La Roche Inc.
- Methods for modifying human antibodies by glycan engineering5 Jul 2022US 11,377,485 B2Academia Sinica
- Method of producing and purifying an active soluble sialyltransferase29 Dec 2015US 9,222,081 B2Biogenerix AG
- Extracellular production of glycosylated products5 Sep 2024US 2024/0294958 A1Inbiose N.V.
- Sialylated Glycoproteins22 Aug 2024US 2024/0279703 A1Momenta Pharmaceuticals, Inc.
- Sialylated Glycoproteins23 May 2024US 2024/0167069 A1Momenta Pharmaceuticals, Inc.
- Sialylated Glycoproteins2 May 2024US 2024/0141401 A1Momenta Pharmaceuticals, Inc.
- Cellular production of glycosylated products14 Mar 2024US 2024/0084347 A1Inbiose N.V.
Most cited
By later US patents